Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)

Next Previous
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms ILLUMINATE-1
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 09 Nov 2021 Results assessing Transcriptional Subsetting of SLE Patient Cohorts Based on Metabolic Pathway Activity from ILLUMINATE-1 clinical trial cohort transcriptomics data set presented at the ACR Convergence 2021
    • 09 Nov 2021 Results assessing Lupus Multivariable Outcome Score (LuMOS) to optimize discrimination between outcomes of actively treated patients versus those randomized to placebo from ILLUMINATE-1 and ILLUMINATE-2 trials, presented at the ACR Convergence 2021.
    • 05 Jun 2021 Data from two phase 3 trials (NCT01196091 and NCT01205438) used to devise a deep learning method uncovers novel pathway associations in systemic lupus erythematosus presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top